FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, and concerns a combination of a proteasome inhibitor and a histone deacetylase inhibitor for tumour cell growth/proliferation inhibition. What is offered is a new combination wherein the proteasome inhibitor is Bortezomib, while the histone deacetylase inhibitor is R3 06465 
. What is also presented is applying said combination for preparing a drug for tumour cell growth/proliferation inhibition, including haematologic cancer cells.
EFFECT: group of inventions provides the new combination with a therapeutic potential showing a synergetic effect of human haematologic cancer cell proliferation inhibition.
5 cl, 8 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION OF A HISTONE DEACETYLASE INHIBITOR AND A PROTEIN KINASE INHIBITOR AND PHARMACEUTICAL APPLICATION THEREOF | 2019 |
|
RU2770754C1 |
| COMBINATION OF LSD1 INHIBITORS FOR TREATING HAEMATOLOGICAL MALIGNANT DISEASES | 2017 |
|
RU2816659C2 |
| COMBINATIONS OF LSD1 INHIBITORS FOR TREATING HAEMATOLOGICAL MALIGNANT DISEASES | 2017 |
|
RU2766259C2 |
| PHARMACEUTICAL COMBINATIONS OF HISTONE DEACETYLASE INHIBITOR AND PROTEASOME INHIBITOR OR IMMUNOMODULATORY DRUG FOR TREATING BLOOD CANCER | 2017 |
|
RU2721409C1 |
| DEACETYLASE INHIBITORS AND THEIR APPLICATION | 2009 |
|
RU2515611C2 |
| DOSAGE FORMS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND THEIR APPLICATION | 2011 |
|
RU2609833C2 |
| PHARMACEUTICAL COMBINATIONS FOR TREATING A MALIGNANT TUMOR | 2017 |
|
RU2726367C2 |
| APPLICATION OF HDAC INHIBITORS FOR TREATING MYELOMA | 2006 |
|
RU2420279C2 |
| SYNTHETIC LETHALITY AND TREATMENT OF CANCER | 2013 |
|
RU2676697C2 |
| METHOD OF INDUCTION OF TERMINAL DIFFERENTIATION | 2003 |
|
RU2320331C2 |
